novarti report posit data intrathec zolgensma type
sma novarti provid data first two dose cohort efficaci data
highest dose cohort present enrol
complet treatment zolgensma sma gene therapi led mean
point improv hfmse recent studi visit
month post-treat addit two patient develop abil
stand independ includ one patient went walk alon
zolgensma efficaci result compar favor current soc biogen
spinraza cherish studi spinraza result hfmse
improv pt month point month
treatment one patient achiev abil stand treat
patient caveat comparison reflect median follow-up
zolgensma trial month zolgensma gener well
toler sae relat elev transaminas level
chang risdiplam thesi investor
spoken expect zolgensma becom soc newborn-screen
young type sma patient today data reinforc perspect
although highlight difficulti compar risdiplam sunfish trial
zolgensma type sma trial refer risdiplam result
point improv similar scale measur call though
risdiplam trial older patient limit cross-trial comparison
median age vs zolgensma trial year old continu
model risdiplam captur market share type opportun
reflect belief risdiplam use patient unabl receiv
gene therapi previous treat
zolgensma experi incomplet respons wane efficaci
time expect potenti occur minor patient
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani focus
develop manufactur small molecul therapeut
address multipl area includ rare disord oncolog
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base probabl
success risdiplam stabl translarna sale post
po aadc gene therapi
grey sky valuat assum valu risdiplam
 premium
 close
compani mention price
